EICHORCondition: Long COVID · Sponsor: ImmunityBio, Inc.
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
This description comes directly from the study's public registry record.
Kayleigh Russell · 424.539.2412 · Kayleigh.Russell@ImmunityBio.com
Jayson Garmizo · 310.912.2230 · Jayson.Garmizo@ImmunityBio.com
Always discuss trial participation with your own doctor first.
| University of California - San Francisco | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07108036